70 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Actbtm3.1(Sirt1)Npa/Actb+ involves: 129/Sv * C57BL/6 * C57BL/6J	abnormal motor coordination/balance	J:160212
	normal behavior/neurological phenotype	J:160212
	decreased body weight	J:160212
	decreased circulating adiponectin level	J:160212
	decreased circulating cholesterol level	J:160212
	decreased circulating free fatty acids level	J:160212
	decreased circulating HDL cholesterol level	J:160212
	decreased circulating insulin level	J:160212
	decreased circulating LDL cholesterol level	J:160212
	decreased circulating leptin level	J:160212
	decreased epididymal fat pad weight	J:160212
	decreased fasting circulating glucose level	J:160212
	delayed fertility	J:160212
	normal homeostasis/metabolism phenotype	J:160212
	improved glucose tolerance	J:160212
	increased food intake	J:160212
	increased oxygen consumption	J:160212
	preweaning lethality, incomplete penetrance	J:160212
Actbtm3.1(Sirt1)Npa/Actb+ Sirt1tm1Mcby/Sirt1tm1Mcby involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6J	normal growth/size/body region phenotype	J:160212
	normal reproductive system phenotype	J:160212
	normal vision/eye phenotype	J:160212
Actbtm3.1(Sirt1)Npa/Actbtm3.1(Sirt1)Npa involves: 129/Sv * C57BL/6 * C57BL/6J	preweaning lethality, complete penetrance	J:160212
ApcMin/Apc+ Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+ involves: 129S4/SvJae * C57BL/6 * C57BL/6J	anemia	J:134301
	cachexia	J:134301
	increased gastrointestinal tumor incidence	J:134301
ApcMin/Apc+ Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+ Tg(Vil1-cre)997Gum/0 involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL	decreased tumor incidence	J:134301
Ccar2tm1Dac/Ccar2tm1Dac Sirt1tm1Ygu/Sirt1tm1Ygu Tg(SERPINA1-cre)1Arge/0 involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6J	decreased susceptibility to diet-induced obesity	J:228688
	normal growth/size/body region phenotype	J:228688
	normal homeostasis/metabolism phenotype	J:228688
Ccdc7aTg(Prnp-Sirt1)10Imai/? B6.Cg-Ccdc7aTg(Prnp-Sirt1)10Imai	abnormal brown adipose tissue physiology	J:203814
	abnormal neuron physiology	J:203814
	abnormal non-rapid eye movement sleep pattern	J:203814
	extended life span	J:203814
	hyperactivity	J:162852, J:203814
	hyperactivity elicited by feed restriction	J:162852
	increased body temperature	J:162852, J:203814
	increased energy expenditure	J:203814
	increased food intake	J:203814
	increased oxygen consumption	J:203814
	increased vertical activity	J:162852
	slow aging	J:203814
Sirt1tm1.1Cxd/Sirt1+ Trp53tm1Brd/Trp53+ either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB/N) or (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N)	abnormal tumor morphology	J:140089
	increased carcinoma incidence	J:140089
	increased lymphoma incidence	J:140089
	increased sarcoma incidence	J:140089
	increased teratoma incidence	J:140089
	increased tumor incidence	J:140089
Sirt1tm1.1Cxd/Sirt1tm1.1Cxd Trp53tm1Brd/Trp53+ either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB/N) or (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N)	decreased survivor rate	J:140089
	embryonic lethality, incomplete penetrance	J:140089
	perinatal lethality, incomplete penetrance	J:140089
Sirt1tm1.1Cxd/Sirt1tm1.1Cxd Trp53tm1Brd/Trp53tm1Brd either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB/N) or (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N)	embryonic lethality, incomplete penetrance	J:140089
	lethality throughout fetal growth and development, incomplete penetrance	J:140089
	perinatal lethality, incomplete penetrance	J:140089
	postnatal lethality, complete penetrance	J:140089
Sirt1tm2.1Mcby/Sirt1tm2.1Mcby involves: 129S1/Sv * 129X1/SvJ	abnormal craniofacial morphology	J:241633
	abnormal eyelid morphology	J:241633
	abnormal lacrimal gland morphology	J:241633
	abnormal salivary gland morphology	J:241633
	decreased body size	J:241633
	hyperpnea	J:241633
	male infertility	J:241633
	perinatal lethality	J:241633
	postnatal lethality, incomplete penetrance	J:180628
Sirt1tm2.1Mcby/Sirt1tm2.1Mcby involves: 129S1/Sv * 129X1/SvJ * CD-1	abnormal energy expenditure	J:180628
	abnormal glucose homeostasis	J:180628
	abnormal glucose tolerance	J:180628
	abnormal spermatogenesis	J:180628
	decreased body size	J:180628
	decreased circulating insulin level	J:180628
	decreased respiratory quotient	J:180628
	decreased white adipose tissue amount	J:180628
	enlarged heart	J:180628
	enlarged pancreas	J:180628
	enlarged spleen	J:180628
	immotile sperm	J:180628
	increased brain size	J:180628
	increased food intake	J:180628
	increased oxygen consumption	J:180628
	male infertility	J:180628
	oligozoospermia	J:180628
	postnatal lethality, incomplete penetrance	J:180628
	short snout	J:180628